U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H17N3O3
Molecular Weight 299.3245
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NIRAXOSTAT

SMILES

CC(C)(C)COC1=C(C=C(C=C1)N2C=C(C=N2)C(O)=O)C#N

InChI

InChIKey=AETHRPHBGJAIBT-UHFFFAOYSA-N
InChI=1S/C16H17N3O3/c1-16(2,3)10-22-14-5-4-13(6-11(14)7-17)19-9-12(8-18-19)15(20)21/h4-6,8-9H,10H2,1-3H3,(H,20,21)

HIDE SMILES / InChI
Y-700 (Niraxostat or 1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid) is an inhibitor of xanthine oxidoreductase. Y-700 demonstrated high oral bioavailability being predominantly eliminated via the liver. It potently reduces serum uric acid levels. Y-700 was in clinical trials for the treatment of gout.

CNS Activity

Curator's Comment: Y-700 (Niraxostat) is CNS active in animals. No human data available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.6 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.54 μg/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAXOSTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.92 μg/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAXOSTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.24 μg/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAXOSTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
106.3 μg × h/mL
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAXOSTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
16.6 μg × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAXOSTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.5 μg × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAXOSTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
27.6 h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAXOSTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
29.8 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAXOSTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
40.2 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NIRAXOSTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
The mechanism of inhibition by xanthine of adenosine A1-receptor responses in rat hippocampus.
2004 Jul 29
Carrier-mediated hepatic uptake of a novel nonrenal excretion type uric acid generation inhibitor, Y-700.
2006 Feb
Preferential inhibition of xanthine oxidase by 2-amino-6-hydroxy-8-mercaptopurine and 2-amino-6-purine thiol.
2007 May 18
[Inhibitors of xanthine oxidoreductase].
2008 Apr
Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury.
2009 Apr
Patents

Sample Use Guides

A single oral dosing of Y-700 (5, 20 or 80 mg) to volunteers caused a dose-dependent reduction of serum uric acid levels indicating close relationship to plasma concentrations of the compound.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
NIRAXOSTAT
INN  
INN  
Official Name English
niraxostat [INN]
Common Name English
Y-700
Code English
1-(3-CYANO-4-(2,2-DIMETHYLPROPOXY)PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID
Systematic Name English
PIRAXOSTAT
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1637
Created by admin on Fri Dec 15 17:18:40 GMT 2023 , Edited by admin on Fri Dec 15 17:18:40 GMT 2023
Code System Code Type Description
CAS
206884-98-2
Created by admin on Fri Dec 15 17:18:40 GMT 2023 , Edited by admin on Fri Dec 15 17:18:40 GMT 2023
PRIMARY
PUBCHEM
449035
Created by admin on Fri Dec 15 17:18:40 GMT 2023 , Edited by admin on Fri Dec 15 17:18:40 GMT 2023
PRIMARY
INN
8778
Created by admin on Fri Dec 15 17:18:40 GMT 2023 , Edited by admin on Fri Dec 15 17:18:40 GMT 2023
PRIMARY
FDA UNII
246FR6022S
Created by admin on Fri Dec 15 17:18:40 GMT 2023 , Edited by admin on Fri Dec 15 17:18:40 GMT 2023
PRIMARY
DRUG BANK
DB03841
Created by admin on Fri Dec 15 17:18:40 GMT 2023 , Edited by admin on Fri Dec 15 17:18:40 GMT 2023
PRIMARY
SMS_ID
300000034283
Created by admin on Fri Dec 15 17:18:40 GMT 2023 , Edited by admin on Fri Dec 15 17:18:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID70174747
Created by admin on Fri Dec 15 17:18:40 GMT 2023 , Edited by admin on Fri Dec 15 17:18:40 GMT 2023
PRIMARY
NCI_THESAURUS
C87293
Created by admin on Fri Dec 15 17:18:40 GMT 2023 , Edited by admin on Fri Dec 15 17:18:40 GMT 2023
PRIMARY